Apellis Pharmaceuticals Net Income
| APLS Stock | USD 20.96 0.68 3.14% |
As of the 1st of March, Apellis Pharmaceuticals shows the mean deviation of 2.56, and Risk Adjusted Performance of 0.0432. Apellis Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Apellis Pharmaceuticals standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Apellis Pharmaceuticals is priced correctly, providing market reflects its regular price of 20.96 per share. Given that Apellis Pharmaceuticals has jensen alpha of 0.1102, we suggest you to validate Apellis Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.
Apellis Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.6748 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 22.4 M | 23.5 M | |
| Net Income From Continuing Ops | 22.4 M | 23.5 M | |
| Net Loss | -587 M | -557.6 M | |
| Net Income Per Share | 0.18 | 0.19 | |
| Net Income Per E B T | 0.93 | 1.09 |
Apellis | Net Income | Build AI portfolio with Apellis Stock |
The evolution of Net Income for Apellis Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Apellis Pharmaceuticals compares to historical norms and industry peers.
Latest Apellis Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Apellis Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Apellis Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Apellis Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Apellis Pharmaceuticals' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apellis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 22.39 M | 10 Years Trend |
|
Net Income |
| Timeline |
Apellis Net Income Regression Statistics
| Arithmetic Mean | (176,911,874) | |
| Coefficient Of Variation | (141.57) | |
| Mean Deviation | 201,546,044 | |
| Median | (46,516,000) | |
| Standard Deviation | 250,460,592 | |
| Sample Variance | 62730.5T | |
| Range | 769.9M | |
| R-Value | (0.44) | |
| Mean Square Error | 53862.3T | |
| R-Squared | 0.20 | |
| Significance | 0.08 | |
| Slope | (21,904,093) | |
| Total Sum of Squares | 1003688.1T |
Apellis Net Income History
Other Fundumenentals of Apellis Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Apellis Pharmaceuticals Net Income component correlations
Apellis Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Apellis Pharmaceuticals is extremely important. It helps to project a fair market value of Apellis Stock properly, considering its historical fundamentals such as Net Income. Since Apellis Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Apellis Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Apellis Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Apellis introduce new products? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.18 | Revenue Per Share | Quarterly Revenue Growth (0.06) | Return On Assets | Return On Equity |
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Apellis Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apellis Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Apellis Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Apellis Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Apellis Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Apellis Pharmaceuticals.
| 12/01/2025 |
| 03/01/2026 |
If you would invest 0.00 in Apellis Pharmaceuticals on December 1, 2025 and sell it all today you would earn a total of 0.00 from holding Apellis Pharmaceuticals or generate 0.0% return on investment in Apellis Pharmaceuticals over 90 days. Apellis Pharmaceuticals is related to or competes with Catalyst Pharmaceuticals, Kiniksa Pharmaceuticals, Mineralys Therapeutics, Beam Therapeutics, Adaptive Biotechnologies, Scholar Rock, and Ideaya Biosciences. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and ... More
Apellis Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Apellis Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Apellis Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.69 | |||
| Information Ratio | 0.021 | |||
| Maximum Drawdown | 25.67 | |||
| Value At Risk | (3.83) | |||
| Potential Upside | 5.01 |
Apellis Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apellis Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Apellis Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Apellis Pharmaceuticals historical prices to predict the future Apellis Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0432 | |||
| Jensen Alpha | 0.1102 | |||
| Total Risk Alpha | (0.22) | |||
| Sortino Ratio | 0.0204 | |||
| Treynor Ratio | 0.2763 |
Apellis Pharmaceuticals March 1, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0432 | |||
| Market Risk Adjusted Performance | 0.2863 | |||
| Mean Deviation | 2.56 | |||
| Semi Deviation | 3.61 | |||
| Downside Deviation | 3.69 | |||
| Coefficient Of Variation | 2162.55 | |||
| Standard Deviation | 3.57 | |||
| Variance | 12.73 | |||
| Information Ratio | 0.021 | |||
| Jensen Alpha | 0.1102 | |||
| Total Risk Alpha | (0.22) | |||
| Sortino Ratio | 0.0204 | |||
| Treynor Ratio | 0.2763 | |||
| Maximum Drawdown | 25.67 | |||
| Value At Risk | (3.83) | |||
| Potential Upside | 5.01 | |||
| Downside Variance | 13.61 | |||
| Semi Variance | 13.03 | |||
| Expected Short fall | (2.81) | |||
| Skewness | (0.83) | |||
| Kurtosis | 4.82 |
Apellis Pharmaceuticals Backtested Returns
Currently, Apellis Pharmaceuticals is not too volatile. Apellis Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0131, which signifies that the company had a 0.0131 % return per unit of standard deviation over the last 3 months. We have found thirty technical indicators for Apellis Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please confirm Apellis Pharmaceuticals' risk adjusted performance of 0.0432, and Mean Deviation of 2.56 to double-check if the risk estimate we provide is consistent with the expected return of 0.0471%. Apellis Pharmaceuticals has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.56, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Apellis Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Apellis Pharmaceuticals is expected to be smaller as well. Apellis Pharmaceuticals right now shows a risk of 3.61%. Please confirm Apellis Pharmaceuticals standard deviation, expected short fall, period momentum indicator, as well as the relationship between the maximum drawdown and rate of daily change , to decide if Apellis Pharmaceuticals will be following its price patterns.
Auto-correlation | 0.71 |
Good predictability
Apellis Pharmaceuticals has good predictability. Overlapping area represents the amount of predictability between Apellis Pharmaceuticals time series from 1st of December 2025 to 15th of January 2026 and 15th of January 2026 to 1st of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Apellis Pharmaceuticals price movement. The serial correlation of 0.71 indicates that around 71.0% of current Apellis Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.71 | |
| Spearman Rank Test | 0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 0.77 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Apellis Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Apellis Pharmaceuticals reported net income of 22.39 M. This is 93.44% lower than that of the Biotechnology sector and 68.04% lower than that of the Health Care industry. The net income for all United States stocks is 96.08% higher than that of the company.
Apellis Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Apellis Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Apellis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Apellis Pharmaceuticals by comparing valuation metrics of similar companies.Apellis Pharmaceuticals is currently under evaluation in net income category among its peers.
Apellis Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Apellis Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Apellis Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Apellis Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Apellis Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Apellis Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Apellis Pharmaceuticals' value.| Shares | Marshall Wace Asset Management Ltd | 2025-06-30 | 2.7 M | Jennison Associates Llc | 2025-06-30 | 2.7 M | Siren, L.l.c. | 2025-06-30 | 2.6 M | Bank Of America Corp | 2025-06-30 | 2.4 M | Norges Bank | 2025-06-30 | 2.4 M | Geode Capital Management, Llc | 2025-06-30 | 2 M | Amundi | 2025-06-30 | 1.6 M | Deutsche Bank Ag | 2025-06-30 | 1.5 M | Orbimed Advisors, Llc | 2025-06-30 | 1.5 M | Venbio Select Advisor Llc | 2025-06-30 | 12.2 M | Ecor1 Capital, Llc | 2025-06-30 | 11.9 M |
Apellis Fundamentals
| Return On Equity | 0.0748 | ||||
| Return On Asset | 0.0353 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 2.68 B | ||||
| Shares Outstanding | 127.83 M | ||||
| Shares Owned By Insiders | 13.82 % | ||||
| Shares Owned By Institutions | 86.18 % | ||||
| Number Of Shares Shorted | 24.68 M | ||||
| Price To Earning | (6.94) X | ||||
| Price To Book | 7.23 X | ||||
| Price To Sales | 2.67 X | ||||
| Revenue | 1 B | ||||
| Gross Profit | 605.69 M | ||||
| EBITDA | 70 M | ||||
| Net Income | 22.39 M | ||||
| Cash And Equivalents | 852.8 M | ||||
| Cash Per Share | 7.76 X | ||||
| Total Debt | 486.31 M | ||||
| Debt To Equity | 0.63 % | ||||
| Current Ratio | 7.57 X | ||||
| Book Value Per Share | 2.92 X | ||||
| Cash Flow From Operations | 45.33 M | ||||
| Short Ratio | 7.15 X | ||||
| Earnings Per Share | 0.18 X | ||||
| Price To Earnings To Growth | (0.30) X | ||||
| Target Price | 33.68 | ||||
| Number Of Employees | 733 | ||||
| Beta | 0.24 | ||||
| Market Capitalization | 2.68 B | ||||
| Total Asset | 1.08 B | ||||
| Retained Earnings | (3.01 B) | ||||
| Working Capital | 691.24 M | ||||
| Current Asset | 115.82 M | ||||
| Current Liabilities | 5.13 M | ||||
| Net Asset | 1.08 B |
About Apellis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apellis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.